| PMV Pharmaceuticals, Inc. |
13.71%7,330,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 14, 2026
|
Apr 24, 2024 |
Increased Nov 6, 2026 |
▲ 3.74 pts |
Increased |
13F: none stated |
| Atea Pharmaceuticals, Inc. |
8.42%6,753,658 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 10, 2026
|
Jul 24, 2023 |
Decreased Nov 6, 2026 |
▼ 0.25 pts |
Decreased |
13F: none stated |
| Aclaris Therapeutics, Inc. |
6.91%10,955,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Oct 30, 2026
|
Feb 2, 2024 |
Decreased Nov 6, 2026 |
▼ 1.23 pts |
Decreased |
13F: none stated |
| Connect Biopharma Holdings Limited |
6.14%3,864,400 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Jul 31, 2026
|
Nov 10, 2025 |
Increased Nov 6, 2026 |
▲ 5.23 pts |
Increased |
13F: none stated |
| Seer, Inc. |
3.95%2,186,587 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 5, 2026
|
Nov 6, 2026 |
— |
— |
New |
13F: none stated |
| Oramed Pharmaceuticals Inc. |
2.13%884,392 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 10, 2026
|
Apr 14, 2023 |
Increased Nov 6, 2026 |
▲ 0.04 pts |
Increased |
13F: none stated |
| Outset Medical Inc. |
13.59%2,519,701 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of May 1, 2026
|
Feb 3, 2026 |
— |
0.00 pts |
— |
13F: none stated |
| Instil Bio, Inc. |
9.52%645,600 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 11, 2026
|
Apr 24, 2024 |
— |
0.00 pts |
— |
13F: none stated |
| Tilly's, Inc. |
7.14%2,150,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of May 2, 2026
|
Feb 13, 2023 |
— |
0.00 pts |
— |
13F: none stated |
| Pliant Therapeutics, Inc. |
2.50%1,546,137 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Aug 7, 2026
|
Feb 3, 2026 |
— |
0.00 pts |
— |
13F: none stated |
| Ikena Oncology, Inc. |
1.77%200,730 shares |
13F, quarter ended Sep 30, 2026filed Nov 6, 2026; % of shares outstanding as of Jul 31, 2026
|
Aug 7, 2024 |
— |
0.00 pts |
— |
13F: none stated |